69. Slevin ML, Clark PI, Joel SP, et al.: A randomized trial to evaluate the effect of schedule on the activity of etopo-side in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989.

70. Toffoli G, Corona G, Basso B, Boiocchi M: Pharmacokinetic optimization of treatment with oral etoposide. Clin Pharmacokinet 43(7):441-466, 2004.

71. Bennett WM, Aronoff GR, Golper TA, et al.: Drug Prescribing in Renal Failure. Philadelphia, PA: American College of Physicians; 1987.

72. Product Information: Vepesid(R), etoposide. Bristol Laboratories, Princeton, NJ, (PI revised 9/1998) reviewed 6/2000.

73. Ettinger LJ, Ettinger AG, Avramis VI, et al.: Acute lym-phoblastic leukemia: a guide to asparaginase and pegas-pargase therapy. BioDrugs 7:30-39, 1997.

74. Lacy CF, Armstrong LL, Goldman MP, Lance LL (eds.): Asparaginase. In: Drug Information Handbook. Hudson: Lexi-comp, Inc.; 1999:88-90.

75. Shepherd GM: Hypersensitivity reactions to chemother-apeutic drugs. Clin Rev Allergy Immunol 24(3):253-262, 2003.

76. Feinberg WM, Swenson MR: Cerebrovascular complications of L-asparaginase therapy. Neurology 38:127-133,

0 0

Post a comment